{"id":"amg-193","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Musculoskeletal pain"}]},"_chembl":{"chemblId":"CHEMBL2109249","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PCSK9, AMG 193 inhibits the degradation of LDL receptors, leading to increased LDL receptor expression on the liver surface and reduced circulating LDL cholesterol levels.","oneSentence":"AMG 193 is a monoclonal antibody targeting PCSK9.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:42.830Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT06333951","phase":"PHASE1","title":"AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-09-17","conditions":"Thoracic Tumors, Non-small Cell Lung Cancer","enrollment":500},{"nctId":"NCT06360354","phase":"PHASE1","title":"A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-05-29","conditions":"Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers","enrollment":350},{"nctId":"NCT06593522","phase":"PHASE2","title":"A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-12-26","conditions":"MTAP-deleted NSCLC","enrollment":200},{"nctId":"NCT05094336","phase":"PHASE1, PHASE2","title":"A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-02-01","conditions":"Advanced MTAP-null Solid Tumors","enrollment":329},{"nctId":"NCT05975073","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2023-08-01","conditions":"MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MTA Cooperative PRMT5 inhibitor"],"phase":"phase_2","status":"active","brandName":"AMG 193","genericName":"AMG 193","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMG 193 is a monoclonal antibody targeting PCSK9. Used for Hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}